A trial to test an antibody as an experimental treatment for Patients with Advanced or Metastatic Solid Tumors (VISTA)

Phase I dose escalation and dose expansion, international, multicenter study of W0180 as single agent and in combination with pembrolizumab (anti-PD-1) in adult participants with locally advanced or metastatic solid tumors.

Hide study title

Status

Status :

Recruiting

Type of study

Phase I

Min. Age

Years old

Max. Age

Gender

All

Brief summary

The objective of this trial is to evaluate the tolerance and the activity of an experimental treatment (called W0180), alone and in combination with an existing immunotherapy treatment (pembrolizumab) in patients with different advanced cancers (large local or distant spread of their tumor) excluding blood cancers.

This is the first time that this treatment (W0180) is tested in humans.

The trial includes 2 parts:

- The dose escalation part to determine the best-tolerated dose

- The dose expansion part to confirm the selected dose and provide additional information on tolerance and treatment activity

Therapeutic area :

Oncology

Disease :

Locally advanced or metastatic solid cancer tumors

Study medication :

Monoclonal antibody W0180

Phase : Phase I

Start Date :

08 September 2020

End Date / Planned study Completion Date :

May 2024

Study ID : W00180IV101